Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System LymphomaYajing Zhao, Ji Ma, Qiang He et al.|Blood and Lymphatic Cancer Targets and Therapy|2025Cited by 0